Emerging from their burrow: Hedgehog pathway inhibitors for cancer |
| |
Authors: | Gregory N. Gan |
| |
Affiliation: | Section of Radiation Oncology, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA |
| |
Abstract: | Introduction: Cancer treatment is moving away from conventional cytotoxic drugs and towards agents that target specific proteins and mechanisms important to cancer development or survival. The Hedgehog Pathway (HhP) is a signal transduction pathway and its constitutive activation is tumorigenic in basal cell carcinoma (BCC). The HhP enables phenotypic flexibility, and channels tumor-stroma interactions. As a result, it is over-expressed in numerous cancers as well as in the tumor microenvironment and may represent a promising therapeutic target.Areas covered: In this article, we review the rationale for targeting HhP and its role as an oncogenic driver, in tumor epithelial-to-mesenchymal transition (EMT), and in the tumor microenvironment and describe the results of preclinical and clinical studies involving HhP inhibitors.Expert opinion: HhP activation plays an important role in both the tumor microenvironment and tumor EMT which can lead to treatment resistance for a number of different malignancies. In addition to standard use in BCC, several HhP inhibitors are in preclinical, early, and mid-stage clinical development for other solid and hematologic malignancies. |
| |
Keywords: | Epithelial-to-mesenchymal transition Hedgehog pathway tumor microenvironment Hedgehog inhibitors |
|
|